Ramón Corbalán2011-08-03
Reestenosis | Síndrome coronario agudo: Estrategia invasiva en SCA-SEST. ¿Urgente o diferida?
Conrad Simpfendorfer.2011-08-04
Reestenosis | Síndrome coronario agudo: Antiplatelet therapy advance in ACS and PCI
Jorge Belardi2011-08-05
Factores de riesgo cardiovascular convencionales y nuevos.
Hernán Prat.2011-08-03
Global adoption of the transradial approach. The end of myths.
Pablo Vázquez2011-08-04
Enfermedad multivaso DES for multivessel PCI
Ajay Kirtane2011-08-04
Enfermedad multivaso A coronary menu: courage, FAME or Syntax.
Conrad Simpfendorfer.2011-08-03
2nd-generation drug-eluting stents, results for “real” patients at two years
Original title: Clinical Outcome Following Stringent Discontinuation of Dual Anti-Platelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents: Two-Year Follow-up of the Randomized TWENTE Trial. Reference: Keneth T, Hanim S, et al. J Am Coll Cardiol 2013. Article in press. In recent years there have been new drug-eluting…
Current hemodialysis patients show similar results for sirolimus-eluting and paclitaxel
Original title: Drug-eluting stents in patients on chronic haemodialysis: Paclitaxel-eluting stents vs. limus –eluting stents Reference: Gabriel l. Sardi, et al. Cardiovasc Revasc Med. 2014 Mar;15(2):86-91. End Stage Renal Disease (ESRD) including renal failure on hemodialysis is associated with coronary heart disease and diabetes with subsequent need for revascularization that in this special population has a high…
Allen’s test may not be necessary to select patients eligible for radial access
Original title: Trans-Radial Coronary Catheterization and Intervention Across the Whole Spectrum of Allen’s test Results. Reference: Marco Valgimigli et al. J Am Coll Cardiol. 2014. Epub ahead of print. Radial access is associated with a chance of occlusion of the vessel in between 0.8 % and 30 % according to different series. Given this fact, the Allen…
Validation of the Bleeding Academic Research Consortium
Reference: Circulation. 2012; 125:1424–143 Abstract: For many years all efforts applied to the optimization of percutaneous coronary intervention (PCI) were aimed specifically at reducing ischemic events risk through the advent of: 1) new devices (medicated stents), reducing restenosis rates, revascularization and 2) development of new drugs with a potent anti-platelet or anticoagulant such as clopidogrel or,…